Table 1.
Relationship between the immunoreactivity of FOXA1 and clinicopathological findings in invasive breast cancer (n = 108)
| Clinical findings | Immunoreactivity score of FOXA1a | |||
|---|---|---|---|---|
| Positive (n = 80) | Negative (n = 28) | P value | ||
| Ageb (mean ± SD) | 59.9 ± 14.8 | 57.1 ± 14.2 | ||
| ≤50 | 23 (21.3 %) | 9 (8.3 %) | 0.92 | |
| >50 | 57 (52.8 %) | 19 (17.6 %) | ||
| pT | ≤20 mm | 44 (48.9 %) | 9 (10.0 %) | 0.047 |
| >20 mm | 23 (25.6 %) | 14 (15.5 %) | ||
| Stage | I, II | 73 (68.2 %) | 28(26.2 %) | 0.31 |
| III, IV | 6 (5.6 %) | 0 (0.0 %) | ||
| Grade | I, II | 58 (70.7 %) | 16 (19.5 %) | 0.024 |
| III | 3 (3.7 %) | 5 (6.1 %) | ||
| ER | Positive (PS ≥ 3) | 56 (51.9 %) | 13 (12.0 %) | 0.025 |
| Negative (PS ≤ 2) | 24 (22.2 %) | 15 (13.9 %) | ||
| PgR | Positive (PS ≥ 3) | 36 (33.3 %) | 5 (4.6 %) | 0.020 |
| Negative (PS ≤ 2) | 44 (40.8 %) | 23 (21.3 %) | ||
| HER2 | Positive | 17 (18.5 %) | 9 (9.8 %) | 0.37 |
| Negative | 51 (55.4 %) | 15 (16.3 %) | ||
| Lymph node | Positive | 28 (31.5 %) | 9 (10.1 %) | 0.92 |
| Negative | 41 (46.1 %) | 11 (12.3 %) | ||
| FOXP1a | Positive | 58 (55.2 %) | 13 (12.4 %) | 0.027 |
| Negative | 21 (20.0 %) | 13 (12.4 %) | ||
All other values represent the number and proportion of cases
ER estrogen receptor, PgR progesterone receptor, TS total score, PS proportion score
aFOXA1 and FOXP1 immunoreactivity scores of 0, 2, and 3–8 were defined as negative and positive immunoreactivity, respectively
bData are presented as the mean ± SD